145 related articles for article (PubMed ID: 9876106)
21. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.
Ohno M; Tanaka Y; Miyamoto M; Takeda T; Hoshi K; Yamada N; Ohtake A
Bioorg Med Chem; 2006 Mar; 14(6):2005-21. PubMed ID: 16297632
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives.
Tai HH; Lee N; Tai CL
Adv Prostaglandin Thromboxane Res; 1980; 6():447-52. PubMed ID: 7189951
[TBL] [Abstract][Full Text] [Related]
23. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
Ackerley N; Brewster AG; Brown GR; Clarke DS; Foubister AJ; Griffin SJ; Hudson JA; Smithers MJ; Whittamore PR
J Med Chem; 1995 May; 38(10):1608-28. PubMed ID: 7752186
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
[TBL] [Abstract][Full Text] [Related]
25. (E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151): a potent, specific thromboxane A2 synthetase inhibitor.
Nishikawa K; Terashita Z; Imamoto T; Imura Y; Hirata M; Terao S
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():523-5. PubMed ID: 2936160
[No Abstract] [Full Text] [Related]
26. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
Cimetière B; Dubuffet T; Landras C; Descombes JJ; Simonet S; Verbeuren TJ; Lavielle G
Bioorg Med Chem Lett; 1998 Jun; 8(11):1381-6. PubMed ID: 9871770
[TBL] [Abstract][Full Text] [Related]
27. Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
Boukli L; Touaibia M; Meddad-Belhabich N; Djimdé A; Park CH; Kim JJ; Yoon JH; Lamouri A; Heymans F
Bioorg Med Chem; 2008 Feb; 16(3):1242-53. PubMed ID: 17993277
[TBL] [Abstract][Full Text] [Related]
28. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the biological activity of azoprostanoids in human platelets.
Gorman RR; Shebuski RJ; Aiken JW; Bundy GL
Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259
[TBL] [Abstract][Full Text] [Related]
30. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
De La Cruz JP; Moreno A; Ruiz-Ruiz MI; Sánchez De La Cuesta F
Thromb Res; 2000 Feb; 97(3):125-31. PubMed ID: 10680643
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
Dogné JM; Wouters J; Rolin S; Michaux C; Pochet L; Durant F; Delarge J; Masereel B
J Pharm Pharmacol; 2001 May; 53(5):669-80. PubMed ID: 11370706
[TBL] [Abstract][Full Text] [Related]
32. [Synthesis and platelet aggregation inhibitory activity of analogues of 4-([2-(1H-imidazol-1-yl)-1-(4-substituted-phenyl)ethoxy]methyl)benzoic acids].
Wu QY; Yang JQ
Yao Xue Xue Bao; 1991; 26(10):741-6. PubMed ID: 1823715
[TBL] [Abstract][Full Text] [Related]
33. Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Trehan AK; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS
Drug Des Discov; 1994 Jan; 11(1):73-89. PubMed ID: 7520762
[TBL] [Abstract][Full Text] [Related]
34. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.
Bhagwat SS; Gude C; Cohen DS; Dotson R; Mathis J; Lee W; Furness P
J Med Chem; 1993 Jan; 36(2):205-10. PubMed ID: 8423593
[TBL] [Abstract][Full Text] [Related]
35. Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acids.
Manley PW; Tuffin DP; Allanson NM; Buckle PE; Lad N; Lai SM; Lunt DO; Porter RA; Wade PJ
J Med Chem; 1987 Oct; 30(10):1812-8. PubMed ID: 3656356
[TBL] [Abstract][Full Text] [Related]
36. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
[TBL] [Abstract][Full Text] [Related]
37. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Murakami M; Oketani K; Inoue T
J Med Chem; 1994 Sep; 37(19):3062-70. PubMed ID: 7932529
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Harada K; Miyamoto K; Yamatsu I
J Med Chem; 1996 Aug; 39(16):3148-57. PubMed ID: 8759636
[TBL] [Abstract][Full Text] [Related]
39. Thromboxane synthetase inhibitors: design and synthesis of a novel series of omega-pyridylalkenoic acids.
Terao S; Kato K; Ohkawa S; Terashita Z; Nishikawa K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():315-7. PubMed ID: 2936112
[No Abstract] [Full Text] [Related]
40. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids.
Kato K; Ohkawa S; Terao S; Terashita Z; Nishikawa K
J Med Chem; 1985 Mar; 28(3):287-94. PubMed ID: 4038746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
